Overview

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:
0

Participant gender:
All

Summary

This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Cyclosporine
Cyclosporins
Tofacitinib

Criteria

Inclusion Criteria:

- Subjects who successfully completed Study A3921030

Exclusion Criteria:

- Subjects who are on the waiting list for a second kidney transplant or any non-renal
organ transplants